670P Discordant pathologic tumor response in primary tumors and lymph nodes after neoadjuvant immune checkpoint inhibition (ICI) in head and neck squamous cell carcinoma (HNSCC)

By A. Luginbuhl, E. Scott, L. Harshyne, E. Flerova, M. Tuluc, S. Gargano, J. Curry, D. Cognetti, A. Argiris, J.M. Johnson. 2022

Subfields: Immunology, Oncology, Otorhinolaryngology

Citations in the corpus

• Heterogeneity of PD-L1 Expression Between the Primary Tumor and Matched Lymph Node Metastases in Head and Neck Squamous Cell Carcinomas (2026, unknown): “These results may offer potential explanations for the varying immunotherapeutic responses of different lesions within the same patient, as observed in recent clinical trials [13,47,48].”